

EMLc

ATC codes: J01GB06

|                          |   |
|--------------------------|---|
| Indication               | Sepsis without septic shock <span>ICD11 code: 1G40</span>   |
| INN                      | Amikacin  |
| Medicine type            | Chemical agent  |
| Antibiotic groups        | <span>A</span> ACCESS   |
| List type                | Core (EML)<br>(EMLc)  |
| Formulations             | Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate) (EMLc)<br>; 50 mg per mL in 2 mL vial (as sulfate) (EMLc)                            |
| EML status history       | First added in 2017 (TRS 1006)<br>Changed in 2021 (TRS 1035)<br>Changed in 2023 (TRS 1049)  |
| Sex                      | All   |
| Age                      | Children (1 month - 12 years)   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |
| Wikipedia                | <a href="#">Amikacin</a>   |
| DrugBank                 | <a href="#">Amikacin</a>   |

## Expert Committee recommendation

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.

## EML recommendations: Sepsis without septic shock

First choice

Second choice

gentamicin

co-prescribed with [amoxicillin](#)

gentamicin

co-prescribed with [ampicillin](#)

gentamicin

co-prescribed with [benzylpenicillin](#)

cefotaxime

ceftriaxone

cloxacillin

co-prescribed with [amikacin](#)

